Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Canaccord Genuity Group

Research analysts at Canaccord Genuity Group assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a “hold” rating and a $165.00 price target on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 2.54% from the company’s current price.

Several other brokerages also recently issued reports on RGEN. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday. They issued a “hold” rating and a $165.00 price target on the stock. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Stock Performance

NASDAQ:RGEN opened at $160.92 on Tuesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The firm’s fifty day simple moving average is $142.66 and its 200-day simple moving average is $141.59. The stock has a market cap of $9.02 billion, a PE ratio of -434.92, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the business posted $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. Analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently made changes to their positions in the business. Andra AP fonden bought a new stake in Repligen during the 2nd quarter worth about $25,000. UMB Bank n.a. raised its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares during the period. Blue Trust Inc. boosted its holdings in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the period. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter worth about $37,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Repligen during the second quarter worth about $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.